Enovis (NYSE:ENOV) Issues Quarterly Earnings Results

Enovis (NYSE:ENOV) released its earnings results on Thursday. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14, FiscalAI reports. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%.The firm had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. During the same period in the prior year, the company posted $0.98 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Enovis updated its FY 2026 guidance to 3.520-3.730 EPS.

Here are the key takeaways from Enovis’ conference call:

• The company delivered solid full-year results with 6% organic revenue growth (Recon +8%, PNR +4%), maintained ~18% adjusted EBITDA margins, returned to positive free cash flow of $20M, and guided 2026 revenue of $2.31B–$2.37B with mid-single-digit organic growth and a targeted 25%+ free cash flow conversion for the year.
• Management recorded a $501 million non-cash goodwill impairment in Q4, which it says does not affect liquidity, cash flows, or debt covenants but highlights valuation pressures on the business.
• Innovation and product momentum accelerated—the company saw 50% more 510(k) clearances than its prior best year, is launching ARVIS with flexible commercial models at AAOS, and reported strong early adoption for Nebula and OrthoDrive alongside double-digit extremities and international Recon growth.
• Near-term headwinds remain from about $15M of tariffs and calendar effects (Q4 had four fewer selling days, a ~400bp organic-growth headwind; Q1 2026 also has two fewer days and a high comparable), which constrained quarterly performance and margin flow-through.

Enovis Trading Up 13.8%

Shares of ENOV traded up $3.07 during trading on Thursday, reaching $25.39. 2,700,237 shares of the company traded hands, compared to its average volume of 1,097,477. Enovis has a twelve month low of $21.00 and a twelve month high of $40.69. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66. The stock has a 50-day simple moving average of $24.30 and a 200-day simple moving average of $28.21. The stock has a market cap of $1.45 billion, a PE ratio of -1.07 and a beta of 1.52.

Insiders Place Their Bets

In related news, EVP Daniel A. Pryor sold 999 shares of Enovis stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Arax Advisory Partners purchased a new stake in Enovis during the fourth quarter worth approximately $29,000. EverSource Wealth Advisors LLC lifted its position in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the last quarter. Danske Bank A S acquired a new position in shares of Enovis in the 3rd quarter valued at $64,000. iSAM Funds UK Ltd purchased a new position in shares of Enovis in the 3rd quarter valued at $80,000. Finally, Brown Brothers Harriman & Co. purchased a new stake in Enovis in the third quarter valued at $90,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ENOV. Wells Fargo & Company increased their price target on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $52.00 price target on shares of Enovis in a report on Thursday. UBS Group restated a “buy” rating and set a $50.00 price objective on shares of Enovis in a research report on Monday, January 5th. Canaccord Genuity Group decreased their target price on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Finally, BTIG Research boosted their target price on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q4 adjusted earnings outpaced estimates — Enovis reported adjusted EPS of $0.95 (beat vs. ~$0.81 consensus), signaling underlying operating profitability despite GAAP noise. Enovis (ENOV) Q4 Earnings Beat Estimates
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $3.52–3.73, above Street expectations — that upward EPS range supports a higher valuation multiple and helped sentiment. Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Street support: BTIG boosted its price target and kept a Buy, and a notable fund added ~$5M to a position, both signaling conviction from some investors/analysts. Benzinga (BTIG price target raise) One Fund Bet $5 Million on Enovis Stock Last Quarter. Shares Surged 14% Post‑Earnings
• Neutral Sentiment: Top‑line growth mixed: full‑year sales grew ~7% (2H momentum in Reconstructive) and Q4 net sales rose ~3%, showing commercial progress but not a breakout. Enovis Announces Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Adjusted metrics remain healthier: adjusted EBITDA and adjusted EPS show profitable operations (adjusted EBITDA/adj. EPS materially positive), which the company highlights as the basis for its guidance. QuiverQuant summary of Enovis results
• Negative Sentiment: Revenue missed Q4 consensus ($575.8M vs. ~$584M expected) and full‑year revenue guidance (~$2.31–2.37B) sits slightly below some Street views — a headwind for growth expectations. Enovis beats earnings but misses on revenue
• Negative Sentiment: Large non‑cash goodwill impairment ($501M Q4, $1.05B FY) produced a substantial GAAP net loss (Q4 and FY), weakening headline earnings, accumulated deficit and some balance‑sheet metrics — a risk for longer‑term investor confidence. QuiverQuant (impairment and GAAP loss details)

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.